The race towards oral weight loss medication has taken another significant turn, and patients across the UK are already asking what it means for them. Foundayo, the brand name for orforglipron, has just been approved in the United States as the first GLP-1 weight loss pill with no food or water restrictions, a genuine milestone in obesity medicine. While it is not yet available in the UK, the announcement has understandably generated a wave of interest from patients who want to know when it might arrive, how it compares to existing treatments, and where they will be able to access it once it does.
At Everest Pharmacy, we like to stay ahead of developments like this so our patients are never left playing catch-up. We also work closely with our online sister site, Everslim, and we can confirm that once Foundayo receives UK approval, it will be made available to patients through both our in-clinic service and Everslim’s online consultation platform, following the same clinical standards we apply to every treatment we offer.
This guide explains exactly what Foundayo is, how it differs from existing GLP-1 treatments, what the clinical trial data shows, and what UK patients should consider while waiting for it to arrive. If you have questions in the meantime, contact our team today.
Quick Answer
Foundayo (orforglipron) was approved in the United States on 1 April 2026 as the first GLP-1 weight loss pill with no food or water restrictions. It is not yet approved in the UK, with private availability expected in 2027 following MHRA review. Once approved, Everest Pharmacy and our online sister site, Everslim, will offer Foundayo in-clinic or online, alongside currently available MHRA-licensed options such as Mounjaro and Wegovy.
What Is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly. It belongs to the same family of medicines as Wegovy (semaglutide) and Mounjaro (tirzepatide), but unlike those two, it does not need to be injected. It was approved by the US Food and Drug Administration on 1 April 2026, making it only the second GLP-1 pill ever approved for weight loss, following Novo Nordisk’s Wegovy pill (oral semaglutide) in December 2025.
What sets Foundayo apart is that it can be taken at any time of day, with or without food, and without any water restrictions. No other oral GLP-1 medicine currently shares this flexibility, and this is a direct result of how the medicine itself is built, rather than a marketing claim.
Why Foundayo Works Differently To Wegovy And Mounjaro
Most GLP-1 medicines, including semaglutide and tirzepatide, are peptides. Peptides are chains of amino acids that are easily broken down by stomach acid, which is why Wegovy and Mounjaro are given as injections rather than tablets. The Wegovy pill gets around this using a special absorption enhancer, but only works if taken on an empty stomach with a small sip of water, thirty minutes before anything else.
Foundayo takes a different approach entirely. It is a small molecule rather than a peptide, meaning it is a simpler, more stable compound that survives digestion and absorbs reliably regardless of food or drink. This is the reason it can be taken flexibly throughout the day, and it is also why manufacturing is expected to be more straightforward and scalable than the complex biological processes required for peptide-based medicines like Wegovy and Mounjaro.
The Foundayo Launch Timeline For The UK
Foundayo is not currently licensed, approved, or legally available in the UK. For it to reach UK patients, Eli Lilly must first secure approval from the Medicines and Healthcare products Regulatory Agency. Lilly has submitted orforglipron for approval in more than forty countries as part of a global rollout, and the UK submission forms part of that wider process.
| Milestone | Status or Estimated Timing |
|---|---|
| FDA approval (US) | 1 April 2026, confirmed |
| MHRA submission | Mid to late 2026, as part of Lilly’s global rollout |
| MHRA decision | Estimated 2027 |
| Private UK availability | Expected 2027, following MHRA approval |
| NHS availability | Subject to a NICE health technology assessment |
These timelines are indicative and subject to the usual regulatory process, so they may shift as things progress. We would always recommend being cautious of any website claiming to supply Foundayo in the UK ahead of official approval, as such products cannot be verified as genuine or safe.
The Evidence Behind Foundayo: The ATTAIN Trials
Foundayo’s approval was supported by the ATTAIN phase 3 clinical trial programme, which enrolled more than 4,500 participants with obesity or overweight. A few key findings stand out:
– In ATTAIN-1, which studied adults with obesity but without type 2 diabetes, patients on the highest dose who remained on treatment lost an average of 12.4% of their body weight over 72 weeks, compared with 0.9% on placebo
– In ATTAIN-2, which studied adults with obesity and type 2 diabetes, patients on the highest dose lost an average of 10.5% of body weight, and HbA1c fell by up to 1.8 percentage points from baseline
– The ATTAIN-MAINTAIN trial specifically looked at whether patients who had already lost weight using injectable GLP-1s could switch to Foundayo for long-term weight maintenance, with early results suggesting this may be a viable approach
– A head-to-head trial called ACHIEVE-3 compared Foundayo directly with oral semaglutide in adults with type 2 diabetes, finding Foundayo produced greater reductions in HbA1c and slightly higher weight loss, though with somewhat higher rates of gastrointestinal side effects and discontinuation
How Effective Is Foundayo Compared To Other GLP-1 Treatments?
Foundayo works, but it does not match the strongest injectable GLP-1 currently available on raw weight loss figures. At the highest approved doses over 72 weeks in clinical trials:
| Treatment | Average Weight Loss | Format | Food Restrictions |
|---|---|---|---|
| Mounjaro (tirzepatide) | Around 20 to 22% | Weekly injection | None |
| Wegovy injection (semaglutide) | Around 15% | Weekly injection | None |
| Wegovy pill (oral semaglutide) | Around 13 to 15% | Daily pill | Empty stomach, 30 minutes before food |
| Foundayo (orforglipron) | Around 11 to 12% | Daily pill | None |
Foundayo’s efficacy sits at the lower end of the GLP-1 spectrum, but a 10 to 12% average weight loss is still clinically meaningful, and considerably more than any non-GLP-1 weight loss medication typically achieves. For many patients, the convenience of a once-daily pill with no restrictions may outweigh the additional few percentage points of weight loss available from injectable options.
How Foundayo Is Dosed
Like other GLP-1 medicines, Foundayo is introduced gradually, starting at a low dose and increasing over several months to help the body adjust and reduce the likelihood of side effects. The FDA-approved US dosing schedule moves through six steps over roughly five months, with a minimum of thirty days at each dose:
– Step one: 0.8 mg once daily for thirty days
– Step two: 2.5 mg once daily for thirty days
– Step three: 5.5 mg once daily for thirty days
– Step four: 9 mg once daily for thirty days
– Step five: 14.5 mg once daily for thirty days
– Step six: 17.2 mg once daily as the ongoing maintenance dose
Not every patient needs to reach the highest dose, and prescribers can hold a patient at a lower dose if it is working well, or slow the titration down if side effects become difficult to manage. The tablet is swallowed whole and should not be broken, crushed, or chewed. This UK-specific dosing information will be confirmed once MHRA approval is granted, as licensing details can vary slightly between regions.
Side Effects To Be Aware Of
Foundayo’s side effect profile is broadly consistent with other GLP-1 medications. The most commonly reported side effects in clinical trials included:
– Nausea, diarrhoea, and vomiting
– Constipation and abdominal bloating
– Indigestion and heartburn
– Headache and fatigue
– Hair loss, which may relate to the rate of weight loss itself rather than being a specific effect of the medication
Most gastrointestinal side effects are mild to moderate, appear most often during the dose escalation stages, and tend to settle as the body adjusts. Serious but rarer risks include pancreatitis, gallbladder problems, and kidney problems linked to severe dehydration from persistent vomiting or diarrhoea. As with other GLP-1 medicines, Foundayo carries a warning regarding thyroid C-cell tumours observed in animal studies, and it is not recommended for anyone with a personal or family history of medullary thyroid carcinoma.
Who Might Not Be Suitable For Foundayo
As with any GLP-1 medication, Foundayo will not be suitable for everyone. Based on current data, it is generally not recommended for those who:
– Have a personal or family history of medullary thyroid carcinoma
– Have Multiple Endocrine Neoplasia syndrome type 2
– Have a history of pancreatitis
– Have significant liver or kidney impairment
– Are pregnant, planning a pregnancy, or breastfeeding
– Have a history of eating disorders
– Are already taking another GLP-1 receptor agonist, such as Mounjaro or Wegovy
A prescriber will always assess individual eligibility once Foundayo becomes available in the UK, typically requiring a BMI of 30 or above, or 27 and above alongside a weight-related health condition.
Why The Foundayo Launch Matters For UK Patients
Even before it reaches the UK, the Foundayo launch matters for a few clear reasons:
– **It removes the needle barrier.** Many patients who could benefit from GLP-1 treatment avoid it purely because of needle anxiety. Foundayo, like the Wegovy pill, opens the door to people who would never consider self-injecting.
– **It offers more flexibility than the Wegovy pill.** The Wegovy pill must be taken on an empty stomach with minimal water thirty minutes before food. Foundayo has no such restrictions, which may make it easier for some patients to stay consistent with treatment.
– **It may support long-term weight maintenance.** The ATTAIN-MAINTAIN trial specifically tested whether patients who had already lost weight on injectable GLP-1s could switch to Foundayo afterwards, which is relevant for anyone currently on Mounjaro or Wegovy thinking about their longer-term plan.
– **Supply is expected to be more reliable.** As a small-molecule tablet, Foundayo can be manufactured using conventional processes, rather than the complex biological manufacturing required for peptide medicines. This may help avoid the kind of supply shortages that have affected injectable GLP-1s in the UK.
What To Do While Waiting For Foundayo In The UK
If you are considering weight loss treatment now, waiting for Foundayo is unlikely to be the most practical option, given the estimated 2027 UK availability. In the meantime, Everest Pharmacy and Everslim can assess you for currently available, MHRA-licensed alternatives, including:
– Mounjaro (tirzepatide), currently the most effective GLP-1 treatment available in the UK, with average weight loss figures notably higher than early Foundayo data
– Wegovy injection (semaglutide), a well-established option with years of real-world UK patient data
– Wegovy pill (oral semaglutide), which is expected to remain the first licensed oral GLP-1 option in the UK, potentially arriving before Foundayo
Whichever route you are exploring, our related guide on Wegovy vs Mounjaro may help you compare the two most established injectable options, and our article on weight loss injections offers useful background if you would like to start sooner rather than wait.
How Everest Pharmacy And Everslim Will Support The Foundayo Launch
Once Foundayo secures MHRA approval, we intend to make it available through both routes patients already know and trust. You will be able to access it via an in-clinic consultation at Everest Pharmacy, where a clinician can assess your suitability face to face, or through our online sister site, Everslim (powered by Everest Pharmacy), which allows patients across the UK to complete their consultation remotely and have treatment delivered directly to their door.
In the meantime, patients can register interest to be notified as soon as Foundayo becomes available through Everslim, ensuring you are not left waiting once UK approval is confirmed.
Frequently Asked Questions
Is Foundayo available in the UK yet?
No. Foundayo is only approved in the United States. UK approval is expected around 2027, subject to MHRA review.
Will Everest Pharmacy offer Foundayo once it is approved?
Yes. Once MHRA approval is granted, Foundayo will be available through Everest Pharmacy in-clinic and online through our sister site, Everslim.
How is Foundayo different from the Wegovy pill?
Foundayo is a small molecule and can be taken at any time, with or without food. The Wegovy pill must be taken on an empty stomach thirty minutes before eating.
Is Foundayo more effective than Mounjaro or Wegovy?
No. Clinical trial data suggests Mounjaro currently produces the greatest average weight loss, followed by Wegovy, with Foundayo slightly lower at around 11 to 12%.
Can I buy Foundayo online in the UK now?
No. Any website claiming to supply Foundayo in the UK ahead of official approval should be treated with caution, as such products cannot be verified as genuine.
What are the side effects of Foundayo?
Commonly reported side effects include nausea, diarrhoea, constipation, and indigestion, most of which are mild and settle as the body adjusts during dose escalation.
What should I do while waiting for Foundayo to launch in the UK?
Consider currently available, MHRA-licensed treatments such as Mounjaro or Wegovy through Everest Pharmacy or Everslim, rather than waiting an uncertain length of time.
Stay Informed About The Foundayo Launch With Everest Pharmacy
The Foundayo launch represents a genuinely exciting development in oral weight loss medication, and we want our patients to be among the first to know once it becomes available in the UK. Whether you are considering waiting for Foundayo or starting treatment sooner with an existing option, our team is here to guide you.
Contact us today to discuss your options, or use one of the buttons below to get started.